Lucid Diagnostics (LUCD) Price & Analysis

Compare

533 Followers

LUCD Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.75 - $1.80

Previous CloseN/A

Volume130.18K

Average Volume (3M)1.40M

Market Cap

$141.34M

Enterprise Value$164.69M

Total Cash (Recent Filing)$31.12M

Total Debt (Recent Filing)$27.55M

Price to Earnings (P/E)―

Beta0.09

Next Earnings

Nov 17, 2025

EPS Estimate

-0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.10

Shares Outstanding137,227,500

10 Day Avg. Volume1,060,851

30 Day Avg. Volume1,400,937

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)7.67

Price to Sales (P/S)9.52

P/FCF Ratio-0.92

Enterprise Value/Market Cap1.17

Enterprise Value/Revenue37.77

Enterprise Value/Gross Profit-58.71

Enterprise Value/Ebitda-3.03

Forecast

1Y Price Target

$2.90

Price Target Upside181.55% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Financial StabilityThe recent public offering raised roughly $25M, providing sufficient capital to support operations through 2026.

Market PotentialThe Medicare price of $1,938 per test suggests a significant total addressable market of around $60 billion.

Revenue PotentialThe company is one step closer to receiving Medicare coverage for EsoGuard, which gives confidence in revenue estimates.

Bears Say

Market CompetitionKey similarities between Lucid's EsoGuard test and Exact's highly successful Cologuard test merit a review.

Regulatory HurdlesIf MolDX reopens its relevant local coverage determination (LCD) and includes EsoGuard, this draft policy would be a critical milestone.

Lucid Diagnostics News

Morning Movers: Oracle powers market higher following ‘blowout’ Q1 results

Stock futures climbed to fresh record highs driven by Oracle’s pre-market performance. The cloud computing giant has soared...

20d ago

GME

AVAV

Lucid Diagnostics 25M share Spot Secondary priced at $1.00

Canaccord and BTIG acted as joint book running managers for the offering. Published first on TheFly – the...

20d ago

LUCD

Closing Bell Movers: Oracle spikes 26% after Q1 results

In the opening hour of the evening session, U.S. equity futures are trading mixed – S&P 500 is...

20d ago

ALB

Lucid Diagnostics announces common stock offering, no amount given

Lucid Diagnostics (LUCD) announced its intention to offer shares of common stock through an underwritten public offering. Canaccord...

21d ago

LUCD

Lucid Diagnostics price target raised to $2.50 from $2 at BTIG

BTIG analyst Mark Massaro raised the firm’s price target on Lucid Diagnostics (LUCD) to $2.50 from $2 and...

25d ago

LUCD

Lucid Diagnostics Appoints John R. Palumbo to Board

The latest announcement is out from Lucid Diagnostics ( ($LUCD) ). On September 25, 2025, Lucid Diagnostics announced...

5d ago

LUCD

Lucid Diagnostics Completes Public Offering for $26.9 Million

Lucid Diagnostics ( ($LUCD) ) has shared an update. On September 11, 2025, Lucid Diagnostics Inc. announced the...

19d ago

LUCD

Lucid Diagnostics Announces Public Stock Offering

Lucid Diagnostics ( ($LUCD) ) has shared an announcement. On September 10, 2025, Lucid Diagnostics entered into an...

20d ago

LUCD

Positive Outlook for Lucid Diagnostics: Medicare Coverage and Clinical Support Boost EsoGuard’s Market Potential

BTIG analyst Mark Massaro has reiterated their bullish stance on LUCD stock, giving a Buy rating on September...

21d ago

LUCD

Positive Outlook on Lucid Diagnostics’ EsoGuard Test Driven by Clinician Support and Potential Medicare Coverage

Analyst Mark Massaro of BTIG reiterated a Buy rating on Lucid Diagnostics, boosting the price target to $2.50....

25d ago

LUCD

Positive Outlook on Lucid Diagnostics Driven by EsoGuard’s Clinical Efficacy and Potential Medicare Coverage

Lucid Diagnostics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from...

25d ago

LUCD

Lucid Diagnostics Earnings Call: Optimism Amid Challenges

Lucid Diagnostics Inc. (($LUCD)) has held its Q2 earnings call. Read on for the main highlights of the...

29d ago

LUCD

Lucid Diagnostics: Strong Financial Performance and Strategic Advancements Justify Buy Rating

Maxim Group analyst Anthony Vendetti has maintained their bullish stance on LUCD stock, giving a Buy rating yesterday....

2M ago

LUCD

Lucid Diagnostics Reports Q2 2025 Earnings

Lucid Diagnostics Inc. ( ($LUCD) ) has released its Q2 earnings. Here is a breakdown of the information...

2M ago

LUCD

LUCD FAQ

What was Lucid Diagnostics’s price range in the past 12 months?

Lucid Diagnostics lowest stock price was $0.75 and its highest was $1.80 in the past 12 months.

What is Lucid Diagnostics’s market cap?

Lucid Diagnostics’s market cap is $141.34M.

When is Lucid Diagnostics’s upcoming earnings report date?

Lucid Diagnostics’s upcoming earnings report date is Nov 17, 2025 which is in 48 days.

How were Lucid Diagnostics’s earnings last quarter?

Lucid Diagnostics released its earnings results on Aug 13, 2025. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.114 by $0.014.

Is Lucid Diagnostics overvalued?

According to Wall Street analysts Lucid Diagnostics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Lucid Diagnostics pay dividends?

Lucid Diagnostics does not currently pay dividends.

What is Lucid Diagnostics’s EPS estimate?

Lucid Diagnostics’s EPS estimate is -0.11.

How many shares outstanding does Lucid Diagnostics have?

Lucid Diagnostics has 137,227,500 shares outstanding.

What happened to Lucid Diagnostics’s price movement after its last earnings report?

Lucid Diagnostics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.114. Following the earnings report the stock price went down -2%.

Which hedge fund is a major shareholder of Lucid Diagnostics?

Currently, no hedge funds are holding shares in LUCD

Lucid Diagnostics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-463.56%

Trailing 12-Months

Asset Growth

13.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Lucid Diagnostics

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Lucid Diagnostics (LUCD) Earnings & Revenues

Historic Earnings Reports

LUCD Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted several positive developments, including significant revenue growth, successful partnerships, and progress toward Medicare coverage. However, challenges remain in terms of revenue recognition and high operational costs. The sentiment is cautiously optimistic with a focus on achieving Medicare coverage as a key milestone.View all LUCD earnings summaries

LUCD Stock 12 Month Forecast

Average Price Target

$2.90

▲(181.55% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","-1":"-$1","0.25":"$0.25","1.5":"$1.5","2.75":"$2.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.25,1.5,2.75,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.4123076923076923,1.5446153846153847,1.676923076923077,1.8092307692307692,1.9415384615384614,2.0738461538461537,2.206153846153846,2.338461538461538,2.4707692307692306,2.603076923076923,2.735384615384615,2.8676923076923075,{"y":3,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.4046153846153846,1.5292307692307692,1.6538461538461537,1.7784615384615385,1.9030769230769229,2.0276923076923077,2.1523076923076925,2.276923076923077,2.401538461538461,2.526153846153846,2.6507692307692308,2.775384615384615,{"y":2.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.28,1.373846153846154,1.4676923076923076,1.5615384615384615,1.6553846153846155,1.7492307692307691,1.843076923076923,1.936923076923077,2.0307692307692307,2.1246153846153844,2.2184615384615385,2.3123076923076926,2.4061538461538463,{"y":2.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.89,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.82,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.48,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.29,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.1,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.28,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >